Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK swooping to buy US biotech IDRx for $1bn - report
10:29am, Wednesday, 08'th Jan 2025
UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of venture capital and priv
GSK and Pfizer's RSV vaccines to carry warnings of neurological disorder risk
06:20pm, Tuesday, 07'th Jan 2025
GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on Tu
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
12:57pm, Tuesday, 07'th Jan 2025
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
GSK's experimental cancer drug wins receives support from US regulator
02:42am, Tuesday, 07'th Jan 2025
GSK PLC (LSE:GSK, NYSE:GSK) has received a major boost for its experimental drug GSK5764227 (GSK'227), which targets a rare and aggressive bone cancer called osteosarcoma. The US Food and Drug Admini
GSK's Nucala approved in China for treating nasal polyps
02:30am, Friday, 03'rd Jan 2025
GSK PLC's (LSE:GSK, NYSE:GSK) Nucala (mepolizumab) has been approved in China to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP) when other therapies, like steroids or surgery, ha
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
03:46am, Friday, 20'th Dec 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based
GSK's cancer drugs meet progression-free survival goal in late-stage trial
02:35am, Friday, 20'th Dec 2024
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
11:46am, Tuesday, 17'th Dec 2024
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
GSK passes three significant milestones with new cancer drug given a double boost
03:21am, Monday, 16'th Dec 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA) has issued a positive opinion recommending the
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
11:21am, Wednesday, 11'th Dec 2024
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
07:00am, Tuesday, 10'th Dec 2024
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
02:00am, Tuesday, 10'th Dec 2024
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying co
GSK says blood cancer drug shows dramatic survival gains in key trial
02:46pm, Monday, 09'th Dec 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. Th
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
01:37pm, Monday, 09'th Dec 2024
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at o
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
12:30pm, Monday, 09'th Dec 2024
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
